Fate Therapeutics (FATE) Equity Average (2016 - 2025)
Fate Therapeutics (FATE) has disclosed Equity Average for 13 consecutive years, with $220.6 million as the latest value for Q4 2025.
- For the quarter ending Q4 2025, Equity Average fell 35.21% year-over-year to $220.6 million, compared with a TTM value of $220.6 million through Dec 2025, down 35.21%, and an annual FY2025 reading of $263.0 million, down 23.46% over the prior year.
- Equity Average was $220.6 million for Q4 2025 at Fate Therapeutics, down from $247.7 million in the prior quarter.
- Across five years, Equity Average topped out at $771.1 million in Q2 2021 and bottomed at $220.6 million in Q4 2025.
- Average Equity Average over 5 years is $471.9 million, with a median of $438.9 million recorded in 2023.
- The sharpest move saw Equity Average surged 153.15% in 2021, then crashed 35.21% in 2025.
- Year by year, Equity Average stood at $704.6 million in 2021, then decreased by 28.9% to $501.0 million in 2022, then dropped by 23.03% to $385.6 million in 2023, then decreased by 11.69% to $340.5 million in 2024, then plummeted by 35.21% to $220.6 million in 2025.
- Business Quant data shows Equity Average for FATE at $220.6 million in Q4 2025, $247.7 million in Q3 2025, and $274.9 million in Q2 2025.